365 related articles for article (PubMed ID: 30032428)
1. A novel dual PPAR-γ agonist/sEH inhibitor treats diabetic complications in a rat model of type 2 diabetes.
Hye Khan MA; Kolb L; Skibba M; Hartmann M; Blöcher R; Proschak E; Imig JD
Diabetologia; 2018 Oct; 61(10):2235-2246. PubMed ID: 30032428
[TBL] [Abstract][Full Text] [Related]
2. Multitarget molecule, PTUPB, to treat diabetic nephropathy in rats.
Khan MAH; Hwang SH; Barnett SD; Stavniichuk A; Jankiewicz WK; Hammock BD; Imig JD
Br J Pharmacol; 2021 Nov; 178(22):4468-4484. PubMed ID: 34255857
[TBL] [Abstract][Full Text] [Related]
3. Dual soluble epoxide hydrolase inhibitor/PPAR-γ agonist attenuates renal fibrosis.
Stavniichuk A; Hye Khan MA; Yeboah MM; Chesnik MA; Jankiewicz WK; Hartmann M; Blöcher R; Kircher T; Savchuk O; Proschak E; Imig JD
Prostaglandins Other Lipid Mediat; 2020 Oct; 150():106472. PubMed ID: 32569747
[TBL] [Abstract][Full Text] [Related]
4. Diabetic nephropathy and long-term treatment effects of rosiglitazone and enalapril in obese ZSF1 rats.
Bilan VP; Salah EM; Bastacky S; Jones HB; Mayers RM; Zinker B; Poucher SM; Tofovic SP
J Endocrinol; 2011 Sep; 210(3):293-308. PubMed ID: 21680617
[TBL] [Abstract][Full Text] [Related]
5. Soluble epoxide hydrolase inhibition and peroxisome proliferator activated receptor γ agonist improve vascular function and decrease renal injury in hypertensive obese rats.
Imig JD; Walsh KA; Hye Khan MA; Nagasawa T; Cherian-Shaw M; Shaw SM; Hammock BD
Exp Biol Med (Maywood); 2012 Dec; 237(12):1402-12. PubMed ID: 23354399
[TBL] [Abstract][Full Text] [Related]
6. Tesaglitazar, a dual PPAR{alpha}/{gamma} agonist, ameliorates glucose and lipid intolerance in obese Zucker rats.
Oakes ND; Thalén P; Hultstrand T; Jacinto S; Camejo G; Wallin B; Ljung B
Am J Physiol Regul Integr Comp Physiol; 2005 Oct; 289(4):R938-46. PubMed ID: 16183630
[TBL] [Abstract][Full Text] [Related]
7. Dynamic blood pressure load and nephropathy in the ZSF1 (fa/fa cp) model of type 2 diabetes.
Griffin KA; Abu-Naser M; Abu-Amarah I; Picken M; Williamson GA; Bidani AK
Am J Physiol Renal Physiol; 2007 Nov; 293(5):F1605-13. PubMed ID: 17728379
[TBL] [Abstract][Full Text] [Related]
8. Empagliflozin improved systolic blood pressure, endothelial dysfunction and heart remodeling in the metabolic syndrome ZSF1 rat.
Park SH; Farooq MA; Gaertner S; Bruckert C; Qureshi AW; Lee HH; Benrahla D; Pollet B; Stephan D; Ohlmann P; Lessinger JM; Mayoux E; Auger C; Morel O; Schini-Kerth VB
Cardiovasc Diabetol; 2020 Feb; 19(1):19. PubMed ID: 32070346
[TBL] [Abstract][Full Text] [Related]
9. Praliciguat inhibits progression of diabetic nephropathy in ZSF1 rats and suppresses inflammation and apoptosis in human renal proximal tubular cells.
Liu G; Shea CM; Jones JE; Price GM; Warren W; Lonie E; Yan S; Currie MG; Profy AT; Masferrer JL; Zimmer DP
Am J Physiol Renal Physiol; 2020 Oct; 319(4):F697-F711. PubMed ID: 32865013
[TBL] [Abstract][Full Text] [Related]
10. N-Benzylbenzamides: A Novel Merged Scaffold for Orally Available Dual Soluble Epoxide Hydrolase/Peroxisome Proliferator-Activated Receptor γ Modulators.
Blöcher R; Lamers C; Wittmann SK; Merk D; Hartmann M; Weizel L; Diehl O; Brüggerhoff A; Boß M; Kaiser A; Schader T; Göbel T; Grundmann M; Angioni C; Heering J; Geisslinger G; Wurglics M; Kostenis E; Brüne B; Steinhilber D; Schubert-Zsilavecz M; Kahnt AS; Proschak E
J Med Chem; 2016 Jan; 59(1):61-81. PubMed ID: 26595749
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic actions of an insulin receptor activator and a novel peroxisome proliferator-activated receptor gamma agonist in the spontaneously hypertensive obese rat model of metabolic syndrome X.
Velliquette RA; Friedman JE; Shao J; Zhang BB; Ernsberger P
J Pharmacol Exp Ther; 2005 Jul; 314(1):422-30. PubMed ID: 15833894
[TBL] [Abstract][Full Text] [Related]
12. A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.
Reifel-Miller A; Otto K; Hawkins E; Barr R; Bensch WR; Bull C; Dana S; Klausing K; Martin JA; Rafaeloff-Phail R; Rafizadeh-Montrose C; Rhodes G; Robey R; Rojo I; Rungta D; Snyder D; Wilbur K; Zhang T; Zink R; Warshawsky A; Brozinick JT
Mol Endocrinol; 2005 Jun; 19(6):1593-605. PubMed ID: 15831517
[TBL] [Abstract][Full Text] [Related]
13. Potent antidiabetic effects of rivoglitazone, a novel peroxisome proliferator-activated receptor-gamma agonist, in obese diabetic rodent models.
Kanda S; Nakashima R; Takahashi K; Tanaka J; Ogawa J; Ogata T; Yachi M; Araki K; Ohsumi J
J Pharmacol Sci; 2009 Oct; 111(2):155-66. PubMed ID: 19809220
[TBL] [Abstract][Full Text] [Related]
14. Peroxisome proliferator-activated receptor (PPAR)-alpha agonism prevents the onset of type 2 diabetes in Zucker diabetic fatty rats: A comparison with PPAR gamma agonism.
Bergeron R; Yao J; Woods JW; Zycband EI; Liu C; Li Z; Adams A; Berger JP; Zhang BB; Moller DE; Doebber TW
Endocrinology; 2006 Sep; 147(9):4252-62. PubMed ID: 16728496
[TBL] [Abstract][Full Text] [Related]
15. A tailored therapy for the metabolic syndrome: the dual peroxisome proliferator-activated receptor-alpha/gamma agonist LY465608 ameliorates insulin resistance and diabetic hyperglycemia while improving cardiovascular risk factors in preclinical models.
Etgen GJ; Oldham BA; Johnson WT; Broderick CL; Montrose CR; Brozinick JT; Misener EA; Bean JS; Bensch WR; Brooks DA; Shuker AJ; Rito CJ; McCarthy JR; Ardecky RJ; Tyhonas JS; Dana SL; Bilakovics JM; Paterniti JR; Ogilvie KM; Liu S; Kauffman RF
Diabetes; 2002 Apr; 51(4):1083-7. PubMed ID: 11916929
[TBL] [Abstract][Full Text] [Related]
16. Nephropathy in model combining genetic hypertension with experimental diabetes. Enalapril versus hydralazine and metoprolol therapy.
Cooper ME; Allen TJ; O'Brien RC; Papazoglou D; Clarke BE; Jerums G; Doyle AE
Diabetes; 1990 Dec; 39(12):1575-9. PubMed ID: 2245881
[TBL] [Abstract][Full Text] [Related]
17. Distinct Endothelial Cell Responses in the Heart and Kidney Microvasculature Characterize the Progression of Heart Failure With Preserved Ejection Fraction in the Obese ZSF1 Rat With Cardiorenal Metabolic Syndrome.
van Dijk CG; Oosterhuis NR; Xu YJ; Brandt M; Paulus WJ; van Heerebeek L; Duncker DJ; Verhaar MC; Fontoura D; Lourenço AP; Leite-Moreira AF; Falcão-Pires I; Joles JA; Cheng C
Circ Heart Fail; 2016 Apr; 9(4):e002760. PubMed ID: 27056881
[TBL] [Abstract][Full Text] [Related]
18. Inhibitors of soluble epoxide hydrolase minimize ischemia-reperfusion-induced cardiac damage in normal, hypertensive, and diabetic rats.
Islam O; Patil P; Goswami SK; Razdan R; Inamdar MN; Rizwan M; Mathew J; Inceoglu B; Stephen Lee KS; Hwang SH; Hammock BD
Cardiovasc Ther; 2017 Jun; 35(3):. PubMed ID: 28296232
[TBL] [Abstract][Full Text] [Related]
19. The effects of dual PPAR
Ericsson A; Tonelius P; Lal M; Sabirsh A; Böttcher G; William-Olsson L; Strömstedt M; Johansson C; Hyberg G; Tapani S; Jönsson-Rylander AC; Unwin R
Physiol Rep; 2017 Mar; 5(5):. PubMed ID: 28292877
[TBL] [Abstract][Full Text] [Related]
20. Resistance to retinopathy development in obese, diabetic and hypertensive ZSF1 rats: an exciting model to identify protective genes.
Caolo V; Roblain Q; Lecomte J; Carai P; Peters L; Cuijpers I; Robinson EL; Derks K; Sergeys J; Noël A; Jones EAV; Moons L; Heymans S
Sci Rep; 2018 Aug; 8(1):11922. PubMed ID: 30093686
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
